While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .
Efficacy of Raloxifen in treatment of fibromyalgia in menopausal women.
BACKGROUND This study compared Raloxifen ( Evista ) with placebo in treatment of fibromyalgia . METHODS One hundred menopausal women with fibromyalgia enrolled in a double-blind r and omized study from Feb 2005 until Oct 2006 . We compared efficacy of Raloxifen , and placebo over 16 weeks of treatment . Fifty patients received Raloxifen 49 of which ( 98 % ) completed the study and 47 ( 94 % ) of 50 patients who received placebo completed the study . Raloxifen in 60 mg or identical placebo dose was given every other day over 16 weeks and patients were followed up . Improved recovery for a treatment group was assessed by a significantly higher mean score from baseline to the end of the treatment trial , compared with patients treated with placebo , on measures of Stanford Health Assessment Question naire ( HAQ ) ; Iranian version of Hospital Anxiety and Depression question naire ( IHAD ) ; sleep disturbance ; number of tender points ; reduction of pain and fatigue based on Visual Analogue Score ( VAS ) . RESULTS Raloxifen produced a significantly higher response rate than placebo in treating fibromyalgia by improving pain and fatigue , reducing of the tender point count , sleep disturbance and recovery of usual activities as measured by the Stanford Health Assessment Question naire ( HAQ ) . The significant effect of Raloxifen on HAD score among patients with fibromyalgia was not seen . CONCLUSION Raloxifen was superior to placebo in the treatment of menopausal patients with fibromyalgia
While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .